Literature DB >> 17764789

Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans.

Nathalie Etchart1, Ana Hennino, Martin Friede, Karima Dahel, Monique Dupouy, Catherine Goujon-Henry, Jean-François Nicolas, Dominique Kaiserlian.   

Abstract

Transcutaneous immunisation (TCI) using a skin patch is a non-invasive vaccination route relevant to mass vaccination against infectious diseases. This phase I/II clinical study, documents that TCI of human adult volunteers with the live-attenuated measles vaccine ROUVAX((R)) is safe and poorly reactogenic. It promotes induction of measles-specific salivary IgA and a tendency to increased frequency of MV-specific IFNgamma-producing T cells. However, in contrast to the subcutaneous route, TCI failed to evoke neutralising MV-specific serum antibodies. Thus, alternative delivery methods and/or devices providing optimal uptake by skin DC should be considered for live-attenuated virus vaccines, such as the measles vaccine.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17764789     DOI： 10.1016/j.vaccine.2007.07.014

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  14 in total

1.  Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization.

Authors:  Laura A Novotny; John D Clements; Lauren O Bakaletz
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

2.  Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.

Authors:  Behazine Combadière; Annika Vogt; Brice Mahé; Dominique Costagliola; Sabrina Hadam; Olivia Bonduelle; Wolfram Sterry; Shlomo Staszewski; Hans Schaefer; Sylvie van der Werf; Christine Katlama; Brigitte Autran; Ulrike Blume-Peytavi
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

3.  Measles vaccination using a microneedle patch.

Authors:  Chris Edens; Marcus L Collins; Jessica Ayers; Paul A Rota; Mark R Prausnitz
Journal:  Vaccine       Date:  2012-10-05       Impact factor: 3.641

Review 4.  The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization.

Authors:  Kamran Badizadegan; James L Goodson; Paul A Rota; Kimberly M Thompson
Journal:  Expert Rev Vaccines       Date:  2020-03-17       Impact factor: 5.217

5.  Characterization of dendritic cells subpopulations in skin and afferent lymph in the swine model.

Authors:  Florian Marquet; Michel Bonneau; Florentina Pascale; Celine Urien; Chantal Kang; Isabelle Schwartz-Cornil; Nicolas Bertho
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

Review 6.  Delivery systems for intradermal vaccination.

Authors:  Y C Kim; C Jarrahian; D Zehrung; S Mitragotri; M R Prausnitz
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

7.  Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces mucosal antibody responses and protects against genital HSV-2 infection.

Authors:  Emilie Bardel; Remi Doucet-Ladeveze; Cyrille Mathieu; Ali M Harandi; Bertrand Dubois; Dominique Kaiserlian
Journal:  NPJ Vaccines       Date:  2016-08-25       Impact factor: 7.344

8.  Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults.

Authors:  Nolwenn Nougarede; Hélène Bisceglia; Aurore Rozières; Catherine Goujon; Florence Boudet; Philippe Laurent; Beatrice Vanbervliet; Karen Rodet; Ana Hennino; Jean-François Nicolas
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial.

Authors:  G Haidari; A Cope; A Miller; S Venables; C Yan; H Ridgers; K Reijonen; D Hannaman; A Spentzou; P Hayes; G Bouliotis; A Vogt; S Joseph; B Combadiere; S McCormack; R J Shattock
Journal:  Sci Rep       Date:  2017-10-12       Impact factor: 4.379

10.  Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.

Authors:  Angus H Forster; Katey Witham; Alexandra C I Depelsenaire; Margaret Veitch; James W Wells; Adam Wheatley; Melinda Pryor; Jason D Lickliter; Barbara Francis; Steve Rockman; Jesse Bodle; Peter Treasure; Julian Hickling; Germain J P Fernando
Journal:  PLoS Med       Date:  2020-03-17       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.